Ventyx Biosciences announced the presentation of data from its Phase 2 trial of the allosteric TYK2 inhibitor VTX958 in Crohn's disease at the 20th Congress of the European Crohn’s and Colitis Organisation (ECCO) from February 19-22, 2025. The trial, which randomized 109 subjects, did not meet its primary endpoint of change from baseline in the Crohn’s disease activity index (CDAI). This outcome was attributed to a higher-than-expected placebo response.
Despite missing the primary endpoint, the study observed a robust, dose-dependent endoscopic response with VTX958. These endoscopic improvements were associated with reductions in key inflammatory markers, including C-reactive protein and fecal calprotectin. The drug was also well tolerated in the Phase 2 trial.
Based on these results, Ventyx Biosciences is continuing the analysis of the Phase 2 data, including information from the 52-week treat-through long-term extension phase. The company is exploring partnership opportunities for VTX958 in Crohn's disease to inform its future development strategy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.